First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

Treatment of frail patients with advanced colorectal cancer (CRC) is controversial. This pilot phase II trial aimed to assess the efficacy and safety of regorafenib when administered in first-line to frail pat...

Source: BMC Cancer - June 3, 2019 Category: Cancer & Oncology Authors: A. Carrato, M. Benavides, B. Massut í, R. Ferreiro-Monteagudo, P. García Alfonso, E. Falcó, M. Reboredo, T. Cano, J. Gallego, J. M. Viéitez, L. Layos, A. Salud, E. Polo, E. Dotor, G. Durán-Ogalla, M. Rodriguez-Garrote & hellip; Tags: Research article Source Type: research